---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-019505"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2023-04-21T23:59:59+00:00"
generated_at: "2026-06-16T21:10:20.107657+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma terminates CEO Mina Sooch, appoints Rick Rodgers as interim CEO

## Summary
- On April 19, 2023, terminated CEO Mina Sooch; Richard Rodgers appointed interim President & CEO.
- Rodgers receives $40,000 monthly salary and 50,000 RSUs vesting in 12 months.
- Rodgers resigned from Audit and Compensation Committees; Gallagher and Manuso filled vacancies.
- Interim CEO to focus on APX3330 Phase 3 path and Nyxol NDA with PDUFA in September 2023.
- Company retained executive search firm to identify a permanent CEO.

## SEC filing metadata
- accession: 0001140361-23-019505
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2023-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/brhc20051717_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-019505
- JSON: https://secwatch.observer/filing/0001140361-23-019505.json
- Plain text: https://secwatch.observer/filing/0001140361-23-019505.txt

## Key facts
- Executive change
  Richard Rodgers was appointed as interim President and Chief Executive Officer at Opus Genetics, Inc..
  - Action: appointed
  - Role: interim President and Chief Executive Officer
  source text: On April 19, 2023, the Board of Directors o f the Company (the “ Board ”) appointed Richard Rodgers as the Company’s interim President and Chief Executive Officer effective as of April 19 , 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm
- Executive change
  Mina Sooch was terminated as President and Chief Executive Officer at Opus Genetics, Inc..
  - Action: terminated
  - Role: President and Chief Executive Officer
  source text: On April 19, 2023, Ocuphire Pharma, Inc. (the “ Company ”) terminated the employment of Mina Sooch, the President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.